Hepatocellular Carcinoma (HCC) Clinical Trials

17 studies are recruiting for hepatocellular carcinoma (hcc) in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

   The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)

   Stage

   Phase 1

   Ages

   18 and older

   Site

   John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey

   Locations

   67 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07291076 on ClinicalTrials.gov

2. Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma

   The goal of this clinical trial is to learn if immunotherapy including nivolumab plus ipilimumab is effective and safe in treating hepatocellular carcinoma.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Texas Southwestern Medical Center, Dallas, Texas

   Run by

   University of Texas Southwestern Medical Center

   See if you can join NCT07689175 on ClinicalTrials.gov

3. A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors

   This study is to evaluate the safety and tolerability to determine (i) the recommended Phase 2 dose (RP2D) of VMD-102 (Phase 1), and (ii) preliminary anti-tumor efficacy (Phase 2), in participants with advanced HCC, metastatic uveal melanoma (MUM), renal cell carcinoma (RCC), non-small cell lung ca…

   Stage

   Phase 1

   Ages

   18 to 75

   Site

   HonorHealth Research Institute, Scottsdale, Arizona

   Run by

   VM Discovery, Inc.

   See if you can join NCT07636785 on ClinicalTrials.gov

4. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

   This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Exelixis Clinical Site #67, Phoenix, Arizona

   Locations

   122 in total

   Run by

   Exelixis

   See if you can join NCT05176483 on ClinicalTrials.gov

5. A Phase 1 Study of the Safety and Tolerability of CTX-10726

   This is a Phase 1, open-label, first-in-human study of CTX-10726 monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 Cohorts: Cohort 1 Dose Escalation and Cohort 2 Dose Expansion.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Nebraska Cancer Specialists, Omaha, Nebraska

   Locations

   5 in total

   Run by

   Compass Therapeutics

   See if you can join NCT07419841 on ClinicalTrials.gov

6. A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer

   Gastrointestinal (GI) cancers remain a major global health burden, largely due to the lack of effective and accessible early screening strategies. Current diagnostic approaches-including endoscopy, computed tomography (CT), and magnetic resonance imaging (MRI)-are either invasive, resource-intensiv…

   Stage

   Not phased

   Ages

   18 and older

   Site

   City of Hope Nat Medical Ctr, Duarte, California

   Run by

   City of Hope Medical Center

   See if you can join NCT07224750 on ClinicalTrials.gov

7. ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma

   Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are AFP-positive/HLA-A2-positive and have relapsed/refractory HB, HCN-NOS, or HCC.

   Stage

   Phase 1

   Ages

   1 to 21

   Site

   Children's Hospital Los Angeles, Los Angeles, California

   Locations

   4 in total

   Run by

   Eureka Therapeutics Inc.

   See if you can join NCT04634357 on ClinicalTrials.gov

8. Project for Multi-Omics-Based Early Detection of Hepatocellular Carcinoma (PROMETHEA Study)

   Hepatocellular carcinoma (HCC) is often diagnosed at an advanced stage, and early detection is critical for improving patient outcomes. Despite this, reliable non-invasive biomarkers for early-stage HCC are limited. This study seeks to develop a multi-omics-based liquid biopsy assay, especially foc…

   Stage

   Not phased

   Ages

   18 and older

   Site

   City of Hope Medical Center, Duarte, California

   Run by

   City of Hope Medical Center

   See if you can join NCT07265271 on ClinicalTrials.gov

9. PSMA PET for the Staging and Management of Hepatocellular Carcinoma

   This prospective, single-center study evaluates the clinical utility of F18-Piflufolastat (PSMA) PET/CT when added to conventional cross-sectional imaging for patients with suspected or confirmed hepatocellular carcinoma (HCC). The study aims to determine whether PSMA PET/CT improves diagnostic acc…

   Stage

   Not phased

   Ages

   18 and older

   Site

   VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California

   Locations

   2 in total

   Run by

   VA Office of Research and Development

   See if you can join NCT07019844 on ClinicalTrials.gov

10. A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

    A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies

    Stage

    Phase 1

    Ages

    16 and older

    Site

    The City of Hope National Medical Center, Duarte, California

    Locations

    6 in total

    Run by

    SEED Therapeutics, Inc.

    See if you can join NCT07197554 on ClinicalTrials.gov

11. Computer Guided Microwave Liver Ablation

    The goal of this clinical trial is to learn if the intraoperative use of a computer guidance software can improve the success of liver tumor ablation in adults. The employed software calculates and displays a simulation of the ablation such that the physician can visualize what portion of the targe…

    Stage

    Not phased

    Ages

    18 to 90

    Site

    Dartmouth HItchcock Medical Center, Lebanon, New Hampshire

    Locations

    2 in total

    Run by

    NE Scientific INC

    See if you can join NCT07226869 on ClinicalTrials.gov

12. Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer

    Hepatocellular carcinoma (HCC) is a major cause of cancer-related deaths globally, with Native Hawaiian and Pacific Islander (NHPI) populations experiencing significantly higher mortality rates compared to other groups in Hawaii. This disparity is influenced by factors such as higher prevalence of …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The Queen's Medical Center, Honolulu, Hawaii

    Locations

    2 in total

    Run by

    University of Hawaii

    See if you can join NCT07075120 on ClinicalTrials.gov

13. Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC

    Phase 1/2 randomized, controlled, open-label trial of theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to identify and treat subjects with GPC3+ unresectable hepatocellular carcinoma (HCC)

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Facility, Birmingham, Alabama

    Locations

    13 in total

    Run by

    RayzeBio, Inc.

    See if you can join NCT06726161 on ClinicalTrials.gov

14. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

    This is a multicenter, randomized, double-blind, parallel-controlled, phase I clinical study to evaluate the PK characteristics, safety, efficacy, and immunogenicity of HLX13 and US-sourced YERVOY® in patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

    Stage

    Phase 1

    Ages

    18 to 65

    Site

    Oncology Physicians Network (OPN) - Los Alamitos /OPN Healthcare, Glendale, California

    Locations

    51 in total

    Run by

    Shanghai Henlius Biotech

    See if you can join NCT07176650 on ClinicalTrials.gov

15. Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90

    The purpose of this study is to determine if baseline liquid biopsy assays (CTC and cf-DNA) as well as single circulating tumor cell-DNA (sCTC DNA) dynamics in the early post-treatment period can predict subsequent treatment response to Y-90 radioembolization in patients with hepatocellular carcino…

    Stage

    Not phased

    Ages

    18 and older

    Site

    VA Palo Alto Health Care System, Palo Alto, California

    Run by

    Palo Alto Veterans Institute for Research

    See if you can join NCT07303712 on ClinicalTrials.gov

16. The Dragon PLC Trial (DRAGON-PLC)

    The goal of the DRAGON PLC clinical trial is to determine whether portal vein embolization (PVE) combined with hepatic vein embolization (HVE) improves resectability and overall survival in patients with initially unresectable primary liver cancer compared to standard PVE alone. This trial specific…

    Stage

    Not phased

    Ages

    18 and older

    Site

    CHU Liège, Liège, Liège

    Locations

    55 in total

    Run by

    Maastricht University

    See if you can join NCT06914648 on ClinicalTrials.gov

17. A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of advanced and/or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic in Arizona, Scottsdale, Arizona

    Locations

    11 in total

    Run by

    GI Innovation, Inc.

    See if you can join NCT05824975 on ClinicalTrials.gov